Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
Forlagets udgivne version, 652 KB, PDF-dokument
The Clinical Trials Subcommittee of the International Headache Society presents the first Health Technology Assessment for the Acute Treatment of Migraine Attacks and Prevention of Migraine. Health technology assessments are systematic evaluations of the properties, effects, and consequences of healthcare technologies; this position statement is designed to inform decision makers about access to and reimbursement for medications and devices for the acute and preventive treatment of migraine. This position statement extends beyond the already available guidelines on randomized controlled trials for migraine to incorporate real-world evidence and a synthetic approach for considering multiple data sources and modelling methods when assessing the value of migraine treatments.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cephalalgia |
Vol/bind | 41 |
Udgave nummer | 3 |
Sider (fra-til) | 279-293 |
Antal sider | 15 |
ISSN | 0333-1024 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Diener reports grants and personal fees from outside the submitted work; HCD received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Alder, Allergan, Amgen, Electrocore, Ipsen, Lilly, Medtronic, Novartis, Pfizer, Teva and Weber & Weber. Electrocore provided financial support for research projects. The German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union support his headache research. HCD serves on the editorial boards of Cephalalgia and Lancet Neurology. HCD chairs the Clinical Guidelines Committee of the German Society of Neurology and is member of the Clinical Trials Committee of the IHS. Dr Ashina reports personal fees from Allergan, personal fees from Amgen, personal fees from Eli Lilly, personal fees from Lundbeck, personal fees from Novartis, grants from Novartis, personal fees from Teva, during the conduct of the study. IDr Durand-Zaleski reports personal fees from Abbvie, personal fees from BMS, personal fees from Boston scientific, personal fees from Medtronic, personal fees from MSD, personal fees from Takeda, personal fees from Astellas, outside the submitted work. Dr Kurth reports personal fees from Lilly, personal fees from Total, personal fees from Newsenselab, personal fees from The BMJ, outside the submitted work. Dr Lanteri-Minet reports personal fees from ALLERGAN, personal fees from AMGEN, personal fees from Astellas, personal fees from ATI, personal fees from BMS, personal fees from Boehringer, personal fees from Boston Scintific, personal fees from Colucid, personal fees from Convergence, personal fees from GlaxoSmithKline, personal fees from Grunenthal, grants and personal fees from Lilly, personal fees from Lundbeck, grants and personal fees from Medtronic, personal fees from MSD, grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Reckitt Benckiser, personal fees from Saint-Jude, personal fees from Sanofi Avantis, grants and personal fees from Teva, personal fees from UCB, personal fees from Zambon, outside the submitted work. Dr Lipton reports personal fees from Acorda Therapeutics, Inc, personal fees from Alder, personal fees from Allergan, personal fees from Amgen Inc., personal fees from Avanir Pharmaceuticals, Inc., personal fees from Biohaven, personal fees from CVS Health, personal fees from Dr. Reddy's, personal fees from Eli Lilly and Company, personal fees from eNeura Therapeutics, personal fees from Merck, personal fees from Novartis, personal fees from Sun Pharmaceutical Industries Inc., personal fees from Supernus Pharmaceuticals, Inc., personal fees from Teva Pharmaceuticals USA, Inc., personal fees from Vector psychometrics, personal fees from Vedanta Research, outside the submitted work; In addition, Wolff's Headache 7th and 8th Edition with royalties paid to Oxford University Press and consult for and have stock options with Biohaven Pharma and eNeura. outside the submitted work Dr Ollendorf reports other from CEA Registry Sponsors, personal fees from EMD Serono, personal fees from Amgen, personal fees from Analysis Group, personal fees from Aspen Institute/U. of Southern California, personal fees from GalbraithWight, personal fees from Cytokinetics, personal fees from Executive Insight, personal fees from Sunovion, personal fees from University of Colorado, outside the submitted work; and I am a former employee of and current collaborator with the Institute for Clinical and Economic Review (ICER), a US-based HTA organization that has evaluated migraine products, outside the submitted work Dr Pozo-Rosich reports having received hnoraria as a consultant or speaker from Allergan, Almirall, Chiesi Spain, Eli Lilly, Biohaven, Novartis and Teva Pharmaceuticals. Her research group has received grants from Novartis, la Caixa Foundation, Instituto Salud Carlos III, PERIS, AGAUR, ERANet Neuron, outside the submitted work. Dr Tassorelli reports personal fees from Allergan, personal fees from Eli Lilly, personal fees from Novartis, personal fees from Teva, during the conduct of the study. Dr Terwindt reports consultancy support from Novartis, Lilly, Teva, and independent support from Dutch Research Council (NWO) and Dutch Brain Foundation.
Publisher Copyright:
© International Headache Society 2021.
ID: 279631357